Pub Date : 2024-09-11eCollection Date: 2024-01-01DOI: 10.14744/hf.2023.2023.0065
Yi-Shan He, Su-Hua Yang, Ze-Yu Huang, Lin Lin, Xue-Cheng Tong, Hong Dai, Yuan Xue
Background and aim: Hepatic encephalopathy (HE) is a neuropsychiatric complication of liver failure with poor outcomes. The present study aimed to evaluate the predictive values of D-dimer in patients with HE.
Materials and methods: Patients with chronic liver failure (CLF) and HE were enrolled. Univariate and multivariate logistic analysis was performed to investigate the risk factors for 1-year mortality of HE.
Results: During the first year after diagnosis, 39.2% (65/166) of the patients died. D-dimer was significantly higher in non-survivors (Z=2.617, p<0.01). Both D-dimer and international normalized ratio (INR) positively correlated with Child-Pugh and MELD scores, and negatively correlated with sodium (all p<0.01). Moreover, there was a negative relationship between D-dimer and HE grades (r=-0.168, p=0.031), while the relationship between INR and HE grades was not significant (r=0.083, p=0.289). Multivariate analysis showed that age (odds ratio (OR):1.035, 95% CI:1.004-1.067, p=0.03), D-dimer (OR=1.138, 95% CI:1.030-1.258, p=0.01), ALT (OR=1.012, 95% CI:1.001-1.022, p=0.03), and sodium (OR=0.920, 95% CI:0.858-0.986, p=0.02) were independent risk factors for 1-year mortality. Then, a new model Model(Age_DD_ALT_Na) incorporating age, D-dimer, ALT, and sodium was developed. AUROC of Model(Age_DD_ALT_Na) was 0.732, which was significantly higher than MELD and Child-Pugh scores (AUROC: 0.602 and 0.599, p=0.013 and 0.022).
Conclusion: D-dimer is a prognostic marker for 1-year mortality in patients with CLF and HE.
背景和目的:肝性脑病(HE)是肝衰竭的一种神经精神并发症,治疗效果不佳。本研究旨在评估 D-二聚体对 HE 患者的预测价值:研究对象为慢性肝衰竭(CLF)和肝性脑病患者。采用单变量和多变量逻辑分析法研究肝衰竭患者1年死亡率的风险因素:结果:确诊后第一年,39.2%(65/166)的患者死亡。非存活者的 D-二聚体明显更高(Z=2.617,p 结论:D-二聚体是一种预后指标:D-二聚体是CLF和HE患者1年死亡率的预后指标。
{"title":"D-dimer is a prognostic marker for 1-year mortality in patients with chronic liver failure and hepatic encephalopathy.","authors":"Yi-Shan He, Su-Hua Yang, Ze-Yu Huang, Lin Lin, Xue-Cheng Tong, Hong Dai, Yuan Xue","doi":"10.14744/hf.2023.2023.0065","DOIUrl":"10.14744/hf.2023.2023.0065","url":null,"abstract":"<p><strong>Background and aim: </strong>Hepatic encephalopathy (HE) is a neuropsychiatric complication of liver failure with poor outcomes. The present study aimed to evaluate the predictive values of D-dimer in patients with HE.</p><p><strong>Materials and methods: </strong>Patients with chronic liver failure (CLF) and HE were enrolled. Univariate and multivariate logistic analysis was performed to investigate the risk factors for 1-year mortality of HE.</p><p><strong>Results: </strong>During the first year after diagnosis, 39.2% (65/166) of the patients died. D-dimer was significantly higher in non-survivors (Z=2.617, p<0.01). Both D-dimer and international normalized ratio (INR) positively correlated with Child-Pugh and MELD scores, and negatively correlated with sodium (all p<0.01). Moreover, there was a negative relationship between D-dimer and HE grades (r=-0.168, p=0.031), while the relationship between INR and HE grades was not significant (r=0.083, p=0.289). Multivariate analysis showed that age (odds ratio (OR):1.035, 95% CI:1.004-1.067, p=0.03), D-dimer (OR=1.138, 95% CI:1.030-1.258, p=0.01), ALT (OR=1.012, 95% CI:1.001-1.022, p=0.03), and sodium (OR=0.920, 95% CI:0.858-0.986, p=0.02) were independent risk factors for 1-year mortality. Then, a new model Model(Age_DD_ALT_Na) incorporating age, D-dimer, ALT, and sodium was developed. AUROC of Model(Age_DD_ALT_Na) was 0.732, which was significantly higher than MELD and Child-Pugh scores (AUROC: 0.602 and 0.599, p=0.013 and 0.022).</p><p><strong>Conclusion: </strong>D-dimer is a prognostic marker for 1-year mortality in patients with CLF and HE.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 4","pages":"193-197"},"PeriodicalIF":1.2,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-10eCollection Date: 2025-01-01DOI: 10.14744/hf.2024.2024.0001
Anusha Alam, Nazli Begum Ozturk, Filiz Akyuz
Hepatopulmonary syndrome (HPS) is a pulmonary complication of liver cirrhosis that causes an oxygenation defect. Many patients are asymptomatic at diagnosis or may have non-specific symptoms such as dyspnea. Since the diagnostic criteria for HPS have been established, its prevalence has been better estimated. HPS is an important prognostic indicator for patients undergoing evaluation for liver transplant. The implementation of the Model for End-stage Liver Disease exception policy has improved the outcomes of HPS; however, the mortality remains high. Here, we discuss the pathophysiology, diagnostic criteria, and recent experimental studies in HPS.
{"title":"Hepatopulmonary syndrome unveiled: Exploring pathogenesis, diagnostic approaches, and therapeutic strategies.","authors":"Anusha Alam, Nazli Begum Ozturk, Filiz Akyuz","doi":"10.14744/hf.2024.2024.0001","DOIUrl":"https://doi.org/10.14744/hf.2024.2024.0001","url":null,"abstract":"<p><p>Hepatopulmonary syndrome (HPS) is a pulmonary complication of liver cirrhosis that causes an oxygenation defect. Many patients are asymptomatic at diagnosis or may have non-specific symptoms such as dyspnea. Since the diagnostic criteria for HPS have been established, its prevalence has been better estimated. HPS is an important prognostic indicator for patients undergoing evaluation for liver transplant. The implementation of the Model for End-stage Liver Disease exception policy has improved the outcomes of HPS; however, the mortality remains high. Here, we discuss the pathophysiology, diagnostic criteria, and recent experimental studies in HPS.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 1","pages":"29-33"},"PeriodicalIF":1.2,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-10eCollection Date: 2025-01-01DOI: 10.14744/hf.2024.2024.0012
George Sarin Zacharia, Anu Jacob
Substance use disorders are a global health problem with detrimental effects on one's health, wealth, and stealth. It includes the use of prescribed medications or the use of illicit drugs in excess amounts or for excess durations associated with complex neuropsychiatric and/or physical manifestations. It affects every organ in the body, and the liver is no exception to the deleterious effects of substance abuse. The mechanism of liver injury varies from agent to agent and may include direct toxic effects, oxidative stress, and inflammatory responses. The hepatic involvement ranges from asymptomatic liver enzyme elevation and fatty liver disease to hepatitis, liver failure, and cirrhosis. Alcohol, the most frequent agent implicated in substance use disorder, is also a prototype hepatotoxin, capable of inducing the whole spectrum of liver diseases. Cigarette smoke contains numerous harmful chemicals, including carcinogens, which can induce liver injury, fibrosis, and HCC. Cocaine, particularly in acute overdose, can result in ischemic hepato-necrosis, while it can also result in clinically inapparent transaminasemia. Marijuana and opiates, despite being associated with numerous deleterious effects, are rarely implicated in clinically apparent liver injury. Individuals with substance use disorder are also prone to viral hepatitis and hepatic insults secondary to hypotension, hypoxia, and other systemic ailments. Liver transplant candidacy in individuals with substance use disorder is a highly complex arena, with guidelines balancing abstinence requirements against evolving evidence on outcomes. This review article provides a thorough analysis of the hepatotoxic repercussions stemming from the agents commonly implicated in substance abuse disorders.
{"title":"Liver disorders in substance abusers.","authors":"George Sarin Zacharia, Anu Jacob","doi":"10.14744/hf.2024.2024.0012","DOIUrl":"https://doi.org/10.14744/hf.2024.2024.0012","url":null,"abstract":"<p><p>Substance use disorders are a global health problem with detrimental effects on one's health, wealth, and stealth. It includes the use of prescribed medications or the use of illicit drugs in excess amounts or for excess durations associated with complex neuropsychiatric and/or physical manifestations. It affects every organ in the body, and the liver is no exception to the deleterious effects of substance abuse. The mechanism of liver injury varies from agent to agent and may include direct toxic effects, oxidative stress, and inflammatory responses. The hepatic involvement ranges from asymptomatic liver enzyme elevation and fatty liver disease to hepatitis, liver failure, and cirrhosis. Alcohol, the most frequent agent implicated in substance use disorder, is also a prototype hepatotoxin, capable of inducing the whole spectrum of liver diseases. Cigarette smoke contains numerous harmful chemicals, including carcinogens, which can induce liver injury, fibrosis, and HCC. Cocaine, particularly in acute overdose, can result in ischemic hepato-necrosis, while it can also result in clinically inapparent transaminasemia. Marijuana and opiates, despite being associated with numerous deleterious effects, are rarely implicated in clinically apparent liver injury. Individuals with substance use disorder are also prone to viral hepatitis and hepatic insults secondary to hypotension, hypoxia, and other systemic ailments. Liver transplant candidacy in individuals with substance use disorder is a highly complex arena, with guidelines balancing abstinence requirements against evolving evidence on outcomes. This review article provides a thorough analysis of the hepatotoxic repercussions stemming from the agents commonly implicated in substance abuse disorders.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 1","pages":"34-40"},"PeriodicalIF":1.2,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-10eCollection Date: 2025-01-01DOI: 10.14744/hf.2023.2023.0067
Muhammet Mikdat Akbas, Mehmet Uzunlulu, Cundullah Torun, Ozgur Bahadir
Background and aim: Hepatorenal syndrome (HRS) is a severe complication of liver cirrhosis with evolving diagnostic criteria. This study aimed to examine HRS prevalence, subtypes, and outcomes while comparing previous and current diagnostic criteria.
Materials and methods: This is a retrospective observational clinical study conducted on hospitalized patients with decompensated cirrhosis. Demographic characteristics, comorbidities, disease duration, disease severity, length of hospitalization, number of rehospitalizations, cirrhosis etiologies, laboratory data, and clinical outcomes were reviewed. The criteria from 2007 by the International Club of Ascites were the previous ones, with the 2015 criteria being the current criteria for diagnosing HRS. The incidence of HRS and its subtypes was determined, and the clinical characteristics of patients with and without HRS were compared using the Mann-Whitney U test.
Results: The study enrolled 212 patients, with a male predominance (57.5%) and a mean age of 63.4±14.5 years. A total of 32.1% of patients developed acute kidney injury (AKI), with prerenal azotemia being the most common type (76.5%), followed by intrinsic renal AKI (23.5%). Under the current criteria, 27 patients (12.7%) received an HRS diagnosis, while under the previous criteria, 16 patients (7.5%) received an HRS diagnosis, and the difference in diagnostic frequencies was statistically significant (p=0.046). In HRS cases, the MELD score (p=0.001), being classified as Child-Pugh C (p=0.043), rehospitalization (p=0.011), requiring intensive care (p=0.001), and creatinine levels (p<0.001) were higher.
Conclusion: AKI is common in hospitalized cirrhotic patients. The current HRS criteria identify more cases that need close monitoring compared to the previous criteria.
背景与目的:肝肾综合征(HRS)是肝硬化的一种严重并发症,诊断标准不断发展。本研究旨在检查HRS的患病率、亚型和结果,同时比较以前和现在的诊断标准。材料与方法:对住院失代偿期肝硬化患者进行回顾性观察性临床研究。回顾了人口统计学特征、合并症、病程、疾病严重程度、住院时间、再住院次数、肝硬化病因、实验室数据和临床结果。国际腹水俱乐部2007年的标准为以前的标准,2015年的标准为目前的HRS诊断标准。确定HRS的发病率及其亚型,并采用Mann-Whitney U检验比较有无HRS患者的临床特征。结果:212例患者入组,男性占57.5%,平均年龄63.4±14.5岁。共有32.1%的患者发生急性肾损伤(AKI),其中最常见的是肾性氮血症(76.5%),其次是内源性肾性AKI(23.5%)。现行标准下HRS诊断27例(12.7%),旧标准下HRS诊断16例(7.5%),诊断频次差异有统计学意义(p=0.046)。在HRS病例中,MELD评分(p=0.001)分为Child-Pugh C (p=0.043)、再住院(p=0.011)、需要重症监护(p=0.001)和肌酐水平(p)。结论:AKI在住院肝硬化患者中很常见。与以前的标准相比,目前的HRS标准确定了更多需要密切监测的病例。
{"title":"Comparison of hepatorenal syndrome incidence and outcomes using previous and current diagnostic criteria in cirrhotic patients.","authors":"Muhammet Mikdat Akbas, Mehmet Uzunlulu, Cundullah Torun, Ozgur Bahadir","doi":"10.14744/hf.2023.2023.0067","DOIUrl":"https://doi.org/10.14744/hf.2023.2023.0067","url":null,"abstract":"<p><strong>Background and aim: </strong>Hepatorenal syndrome (HRS) is a severe complication of liver cirrhosis with evolving diagnostic criteria. This study aimed to examine HRS prevalence, subtypes, and outcomes while comparing previous and current diagnostic criteria.</p><p><strong>Materials and methods: </strong>This is a retrospective observational clinical study conducted on hospitalized patients with decompensated cirrhosis. Demographic characteristics, comorbidities, disease duration, disease severity, length of hospitalization, number of rehospitalizations, cirrhosis etiologies, laboratory data, and clinical outcomes were reviewed. The criteria from 2007 by the International Club of Ascites were the previous ones, with the 2015 criteria being the current criteria for diagnosing HRS. The incidence of HRS and its subtypes was determined, and the clinical characteristics of patients with and without HRS were compared using the Mann-Whitney U test.</p><p><strong>Results: </strong>The study enrolled 212 patients, with a male predominance (57.5%) and a mean age of 63.4±14.5 years. A total of 32.1% of patients developed acute kidney injury (AKI), with prerenal azotemia being the most common type (76.5%), followed by intrinsic renal AKI (23.5%). Under the current criteria, 27 patients (12.7%) received an HRS diagnosis, while under the previous criteria, 16 patients (7.5%) received an HRS diagnosis, and the difference in diagnostic frequencies was statistically significant (p=0.046). In HRS cases, the MELD score (p=0.001), being classified as Child-Pugh C (p=0.043), rehospitalization (p=0.011), requiring intensive care (p=0.001), and creatinine levels (p<0.001) were higher.</p><p><strong>Conclusion: </strong>AKI is common in hospitalized cirrhotic patients. The current HRS criteria identify more cases that need close monitoring compared to the previous criteria.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 1","pages":"5-10"},"PeriodicalIF":1.2,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-10eCollection Date: 2025-01-01DOI: 10.14744/hf.2023.2023.0047
Shakir Ali, Cem Aygun, Ibrahim Halil Bahcecioglu
Drug dose efficacy/toxicity depends on a number of factors including genetic and nongenetic factors, a pre-existing disease, and coadministration of other substances and drugs. Cytochrome P450 (CYP) proteins play a crucial role in drug metabolism where they catalyse a number of Phase I oxidation reactions. Concurrently administered drugs and substances, besides the CYP genotype are crucial and can induce/inhibit the CYP activity, thus affecting drug biotransformation and its bioavailability, compromising with drug efficacy, or even causing toxicity due to slow metabolism. Hepatic CYP is particularly important as it metabolizes about ¾ of all drugs. Determining the metabolite/drug ratio (in vivo CYP phenotyping) can be an important tool that can help in drug dose optimization for the drugs metabolized by specific CYPs as the genotype may not always reflect the true enzyme activity. Clinically important CYP isoforms commonly reported in drug oxidation reactions and which mainly include CYP3A4/5, CYP2C19, CYP2C9 and CYP2D6 need to be analysed for their activity in vivo, in at least the cases of unpredictable treatment outcomes. The activity levels of other less commonly reported but no less important CYPs, such as CYP2B6, one of the most polymorphic human CYP involved in the metabolism of artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine and methadone, and reported for its high inter-individuals and within-individual variability may also be determined on a case-to-case basis. This review highlights the variations in CYP activity due to various reasons and the importance of in vivo phenotyping over genotype in ascertaining drug bioavailability and dose optimization, implicating metabolite/drug ratio determination for personalized treatment of especially chronic liver disease patients.
{"title":"Phenoconversion and <i>in vivo</i> phenotyping of hepatic cytochrome P450: Implications in predictive precision medicine and personalized therapy.","authors":"Shakir Ali, Cem Aygun, Ibrahim Halil Bahcecioglu","doi":"10.14744/hf.2023.2023.0047","DOIUrl":"10.14744/hf.2023.2023.0047","url":null,"abstract":"<p><p>Drug dose efficacy/toxicity depends on a number of factors including genetic and nongenetic factors, a pre-existing disease, and coadministration of other substances and drugs. Cytochrome P450 (CYP) proteins play a crucial role in drug metabolism where they catalyse a number of Phase I oxidation reactions. Concurrently administered drugs and substances, besides the CYP genotype are crucial and can induce/inhibit the CYP activity, thus affecting drug biotransformation and its bioavailability, compromising with drug efficacy, or even causing toxicity due to slow metabolism. Hepatic CYP is particularly important as it metabolizes about ¾ of all drugs. Determining the metabolite/drug ratio (<i>in vivo</i> CYP phenotyping) can be an important tool that can help in drug dose optimization for the drugs metabolized by specific CYPs as the genotype may not always reflect the true enzyme activity. Clinically important CYP isoforms commonly reported in drug oxidation reactions and which mainly include CYP3A4/5, CYP2C19, CYP2C9 and CYP2D6 need to be analysed for their activity <i>in vivo</i>, in at least the cases of unpredictable treatment outcomes. The activity levels of other less commonly reported but no less important CYPs, such as CYP2B6, one of the most polymorphic human CYP involved in the metabolism of artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine and methadone, and reported for its high inter-individuals and within-individual variability may also be determined on a case-to-case basis. This review highlights the variations in CYP activity due to various reasons and the importance of <i>in vivo</i> phenotyping over genotype in ascertaining drug bioavailability and dose optimization, implicating metabolite/drug ratio determination for personalized treatment of especially chronic liver disease patients.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 3","pages":"121-128"},"PeriodicalIF":1.2,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-10eCollection Date: 2024-01-01DOI: 10.14744/hf.2024.2024.0010
Ali Riza Caliskan, Mehmet Ali Erdogan
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, potentially life-threatening, drug-induced hypersensitivity reaction that involves hematological abnormalities (atypical lymphocytosis, eosinophilia), lymphadenopathy, skin eruption, and internal organ involvement (lung, liver, kidney). The 36-year-old female patient was followed by bloody diarrhea, diffuse skin rashes and hepatitis. She was diagnosed with psoriatic arthritis, and Leflunomide 20 mg was added to the treatment six weeks ago. Upon developing hepatic encephalopathy and deepening the fulminant liver failure during the follow-up, a living donor liver from her son was transplanted on the 4th day of hospitalization. The patient had deceased on the second day after liver transplantation due to multiple organ failures. In the literature, mortality in DRESS syndrome is mostly secondary to hepatic failure. Liver transplantation cannot be effective due to systemic involvement and recurrence in the transplanted liver.
{"title":"Leflunomide induced fatal dress syndrome need liver transplantation.","authors":"Ali Riza Caliskan, Mehmet Ali Erdogan","doi":"10.14744/hf.2024.2024.0010","DOIUrl":"10.14744/hf.2024.2024.0010","url":null,"abstract":"<p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, potentially life-threatening, drug-induced hypersensitivity reaction that involves hematological abnormalities (atypical lymphocytosis, eosinophilia), lymphadenopathy, skin eruption, and internal organ involvement (lung, liver, kidney). The 36-year-old female patient was followed by bloody diarrhea, diffuse skin rashes and hepatitis. She was diagnosed with psoriatic arthritis, and Leflunomide 20 mg was added to the treatment six weeks ago. Upon developing hepatic encephalopathy and deepening the fulminant liver failure during the follow-up, a living donor liver from her son was transplanted on the 4<sup>th</sup> day of hospitalization. The patient had deceased on the second day after liver transplantation due to multiple organ failures. In the literature, mortality in DRESS syndrome is mostly secondary to hepatic failure. Liver transplantation cannot be effective due to systemic involvement and recurrence in the transplanted liver.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 4","pages":"204-206"},"PeriodicalIF":1.2,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background and aim: The aim of this study was to evaluate the role of intrabiliary pressure (IBP) in the pathophysiology of extrahepatic biliary obstruction (EHBO) during percutaneous transhepatic biliary drainage (PTBD).
Materials and methods: Adult patients with EHBO who underwent PTBD were prospectively enrolled. IBP was recorded during primary PTBD. The parameters of interest were age, gender, etiology of EHBO, baseline and post-PTBD liver function tests, duration for resolution of jaundice (decrease in total serum bilirubin ≥30% of baseline or <2 mg/dL), cholangitis, bile cultures, and serum albumin levels. The level of EHBO was divided into three types: Type 1 - secondary biliary confluence involved; Type 2 - primary biliary confluence involved; Type 3 - mid and distal common bile duct obstruction.
Results: IBP was measured in 102 patients, and finally, 87 patients, including 52 (59.77%) females, were analyzed. The mean age of the patients was 56.1±11.6 years. The most common etiology of EHBO was carcinoma of the gallbladder in 44 (50.6%) patients. The mean IBP was 18.41±3.91 mmHg. IBP was significantly higher in Type 3 EHBO compared to Type 1 and 2 (p=0.012). A significant correlation was seen between IBP and baseline total serum bilirubin (p<0.01). There was a negative correlation between IBP and baseline serum albumin (p=0.017). In 56.3% of patients, resolution of jaundice was observed by day 3, but this was not significantly associated with IBP (p=0.19). There was no correlation between IBP and cholangitis (p=0.97) or bacterial cultures (p=0.21).
Conclusion: IBP was significantly associated with the type of EHBO, baseline serum bilirubin, and albumin levels. IBP could not predict cholangitis or the resolution of jaundice after PTBD.
{"title":"Intrabiliary pressure in the pathophysiology of extra hepatic biliary obstruction.","authors":"Dhananjay Saxena, Shridhar Vasantrao Sasturkar, Amar Mukund, Yashwant Patidar, Ashok Kumar Choudhury, Ragini Kilambi, Pratibha Kale","doi":"10.14744/hf.2023.2023.0066","DOIUrl":"10.14744/hf.2023.2023.0066","url":null,"abstract":"<p><strong>Background and aim: </strong>The aim of this study was to evaluate the role of intrabiliary pressure (IBP) in the pathophysiology of extrahepatic biliary obstruction (EHBO) during percutaneous transhepatic biliary drainage (PTBD).</p><p><strong>Materials and methods: </strong>Adult patients with EHBO who underwent PTBD were prospectively enrolled. IBP was recorded during primary PTBD. The parameters of interest were age, gender, etiology of EHBO, baseline and post-PTBD liver function tests, duration for resolution of jaundice (decrease in total serum bilirubin ≥30% of baseline or <2 mg/dL), cholangitis, bile cultures, and serum albumin levels. The level of EHBO was divided into three types: Type 1 - secondary biliary confluence involved; Type 2 - primary biliary confluence involved; Type 3 - mid and distal common bile duct obstruction.</p><p><strong>Results: </strong>IBP was measured in 102 patients, and finally, 87 patients, including 52 (59.77%) females, were analyzed. The mean age of the patients was 56.1±11.6 years. The most common etiology of EHBO was carcinoma of the gallbladder in 44 (50.6%) patients. The mean IBP was 18.41±3.91 mmHg. IBP was significantly higher in Type 3 EHBO compared to Type 1 and 2 (p=0.012). A significant correlation was seen between IBP and baseline total serum bilirubin (p<0.01). There was a negative correlation between IBP and baseline serum albumin (p=0.017). In 56.3% of patients, resolution of jaundice was observed by day 3, but this was not significantly associated with IBP (p=0.19). There was no correlation between IBP and cholangitis (p=0.97) or bacterial cultures (p=0.21).</p><p><strong>Conclusion: </strong>IBP was significantly associated with the type of EHBO, baseline serum bilirubin, and albumin levels. IBP could not predict cholangitis or the resolution of jaundice after PTBD.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 4","pages":"198-203"},"PeriodicalIF":1.2,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01eCollection Date: 2024-01-01DOI: 10.14744/hf.2023.2023.0037
Gabriela S Martins, Carlos Gustavo S Rosa, Elizangela G Schemitt, Josieli R Colares, Sandielly Rb Fonseca, Marilda S Brasil, Millena O Engeroff, Norma P Marroni
Background and aim: Cirrhosis is characterized by structural and functional alterations of the liver. Melatonin (MLT) has antioxidant properties. Physical exercise (EX) can reverse muscle loss in cirrhotic patients. The objective was to evaluate the action of MLT and EX on the liver of rats subjected to the experimental model of bile duct ligation (BLD).
Materials and methods: 48 male Wistar rats were used, divided into groups: Control (CO), CO+MLT, CO+EX, CO+MLT+EX, BDL, BDL+MLT, BDL+EX, and BDL+MLT+EX. The treatments occurred from the 15th to the 28th day. The dose of MLT was 20 mg/kg via I.p (1x/day), and the EX was performed 10 min/day. Blood and liver were collected for analysis.
Results: The liver integrity enzymes AST, ALT, and ALP showed a significant reduction in the groups treated with MLT and EX. Histological analyses showed reorganization of the liver parenchyma, reduction of inflammatory infiltrate, and fibrotic nodules. Lipoperoxidation (LPO), the activity of antioxidant enzymes, and nitric oxide metabolites showed a significant reduction in the groups treated with MLT and EX. The expression of TNF-α and NF-kB decreased in the treated groups.
Conclusion: Melatonin and physical exercise seem to be effective in restoring the parameters evaluated in this model of experimental cirrhosis.
背景和目的:肝硬化以肝脏结构和功能改变为特征。褪黑素(MLT)具有抗氧化作用。体育锻炼(EX)可逆转肝硬化患者的肌肉损失。材料和方法:使用 48 只雄性 Wistar 大鼠,分为对照组(CO)、CO+MLT 组(CO+MLT 组)和 EX 组(EX 组):对照组(CO)、CO+MLT 组、CO+EX 组、CO+MLT+EX 组、BDL 组、BDL+MLT 组、BDL+EX 组和 BDL+MLT+EX 组。治疗时间为第 15 天至第 28 天。MLT的剂量为20毫克/千克,经静脉注射(1次/天),EX的剂量为10分钟/天。采集血液和肝脏进行分析:结果:接受 MLT 和 EX 治疗组的肝脏完整性酶 AST、ALT 和 ALP 显著降低。组织学分析表明,肝实质重组,炎症浸润和纤维化结节减少。脂肪过氧化(LPO)、抗氧化酶活性和一氧化氮代谢物在接受 MLT 和 EX 治疗的组别中显著减少。结论:结论:褪黑素和体育锻炼似乎能有效恢复实验性肝硬化模型中的评估指标。
{"title":"Action of melatonin and physical exercise on the liver of cirrhotic rats: Study of oxidative stress and the inflammatory process.","authors":"Gabriela S Martins, Carlos Gustavo S Rosa, Elizangela G Schemitt, Josieli R Colares, Sandielly Rb Fonseca, Marilda S Brasil, Millena O Engeroff, Norma P Marroni","doi":"10.14744/hf.2023.2023.0037","DOIUrl":"10.14744/hf.2023.2023.0037","url":null,"abstract":"<p><strong>Background and aim: </strong>Cirrhosis is characterized by structural and functional alterations of the liver. Melatonin (MLT) has antioxidant properties. Physical exercise (EX) can reverse muscle loss in cirrhotic patients. The objective was to evaluate the action of MLT and EX on the liver of rats subjected to the experimental model of bile duct ligation (BLD).</p><p><strong>Materials and methods: </strong>48 male Wistar rats were used, divided into groups: Control (CO), CO+MLT, CO+EX, CO+MLT+EX, BDL, BDL+MLT, BDL+EX, and BDL+MLT+EX. The treatments occurred from the 15<sup>th</sup> to the 28<sup>th</sup> day. The dose of MLT was 20 mg/kg via I.p (1x/day), and the EX was performed 10 min/day. Blood and liver were collected for analysis.</p><p><strong>Results: </strong>The liver integrity enzymes AST, ALT, and ALP showed a significant reduction in the groups treated with MLT and EX. Histological analyses showed reorganization of the liver parenchyma, reduction of inflammatory infiltrate, and fibrotic nodules. Lipoperoxidation (LPO), the activity of antioxidant enzymes, and nitric oxide metabolites showed a significant reduction in the groups treated with MLT and EX. The expression of TNF-α and NF-kB decreased in the treated groups.</p><p><strong>Conclusion: </strong>Melatonin and physical exercise seem to be effective in restoring the parameters evaluated in this model of experimental cirrhosis.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 4","pages":"184-192"},"PeriodicalIF":1.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-02eCollection Date: 2024-01-01DOI: 10.14744/hf.2023.2023.0049
Huseyin Karaaslan, Hasan Inan, Alper Tunga Turkmen, Ismail Altintas, Nida Uyar, Mehmet Ali Eren
Background and aim: The triglyceride glucose index (TyG) has been proposed as a promising indicator of both insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD). However, the efficacy of the TyG index in predicting NAFLD has not been adequately studied, particularly in obese individuals.
Materials and methods: We analyzed 190 morbidly obese individuals. The TyG index, anthropometric obesity indices, homeostatic model assessment (HOMA-IR), and biochemical parameters were compared. NAFLD was diagnosed by hepatic ultrasonography and classified into four grades (0, 1, 2, and 3). Individuals in grades 2 and 3 are considered to have severe steatosis, while those in grades 0 and 1 do not.
Results: The area under the curve (AUC) values of the TyG index, body mass index, neck circumferences, waist-to-hip ratio, and HOMA-IR did not differ significantly in predicting severe steatosis (0.640, 0.742, 0.725, 0.620, and 0.624 respectively). However, the AUC values of waist circumference and alanine aminotransferase provided better predictions than the TyG index (0.782, 0.744, and 0.640 respectively).
Conclusion: The TyG index is highly effective in predicting both the presence and severity of NAFLD. However, it did not outperform simple obesity indices in predicting NAFLD and its severity in obese patients.
{"title":"Comparison of triglyceride-glucose index and anthropometric obesity indices in predicting severe grades of hepatic steatosis in nonalcoholic fatty liver disease among non-diabetic obese individuals.","authors":"Huseyin Karaaslan, Hasan Inan, Alper Tunga Turkmen, Ismail Altintas, Nida Uyar, Mehmet Ali Eren","doi":"10.14744/hf.2023.2023.0049","DOIUrl":"10.14744/hf.2023.2023.0049","url":null,"abstract":"<p><strong>Background and aim: </strong>The triglyceride glucose index (TyG) has been proposed as a promising indicator of both insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD). However, the efficacy of the TyG index in predicting NAFLD has not been adequately studied, particularly in obese individuals.</p><p><strong>Materials and methods: </strong>We analyzed 190 morbidly obese individuals. The TyG index, anthropometric obesity indices, homeostatic model assessment (HOMA-IR), and biochemical parameters were compared. NAFLD was diagnosed by hepatic ultrasonography and classified into four grades (0, 1, 2, and 3). Individuals in grades 2 and 3 are considered to have severe steatosis, while those in grades 0 and 1 do not.</p><p><strong>Results: </strong>The area under the curve (AUC) values of the TyG index, body mass index, neck circumferences, waist-to-hip ratio, and HOMA-IR did not differ significantly in predicting severe steatosis (0.640, 0.742, 0.725, 0.620, and 0.624 respectively). However, the AUC values of waist circumference and alanine aminotransferase provided better predictions than the TyG index (0.782, 0.744, and 0.640 respectively).</p><p><strong>Conclusion: </strong>The TyG index is highly effective in predicting both the presence and severity of NAFLD. However, it did not outperform simple obesity indices in predicting NAFLD and its severity in obese patients.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 3","pages":"113-119"},"PeriodicalIF":1.2,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11237241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}